Charles River has been conducting efficacy studies to support early ocular drug development for 20 years. Our expert staff works with local board-certified veterinary ophthalmologists and leading-edge technologies, such as optical coherence tomography (OCT), to provide unmatched ophthalmic drug discovery services.
Our scientists and technical staff have experience with a diverse range of therapeutics, including biologics, small molecules, gene therapy and cell therapy for ocular indications, and the ability to administer these agents via both common and novel ocular dose routes.
In addition, we offer supplementary services for your ocular program, including electroretinography, tonometry (IOP) evaluations, digital fundus photography, pachymetry (corneal thickness measurement), vitrectomy, quantitative autoradiography, drug metabolism techniques and enhanced microscopic evaluation.